Pliant Therapeutics Inc (PLRX) Actualités

Form PRE 14A - Other preliminary proxy statements

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX...

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date...

Form 8-K - Current report

Form 8-A12B - Registration of securities [Section 12(b)]

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO...

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX...

Form 8-K - Current report

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today...

Form 8-K - Current report

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase...

Form 4 - Statement of changes in beneficial ownership of securities